Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Sex hormone-binding globulin (SHBG): Identification of the molecular mechanisms that regulate its expression and role in body fat distribution and in the development of type 2 diabetes

IP: David Martinez Selva
Collaborators: Rafael Simó Canonge, Cristina Hernández Pascual
Funding agency: Instituto de Salud Carlos III
Funding: 42000
Reference: CP08/00058
Duration: 01/01/2009 - 31/12/2011

Sex hormone-binding globulin (SHBG): Identification of the molecular mechanisms that regulate its expression and role in body fat distribution and in the development of type 2 diabetes

IP: Rafael Simó Canonge
Collaborators: David Martinez Selva, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 247050
Reference: MS08/00058
Duration: 01/02/2009 - 31/01/2015

Unidad Central de Investigación en Ensayos Clínicos Vall d'Hebron (UCIEC-VH)

IP: Rafael Simó Canonge
Collaborators: Manuel Hernández González, Joan Montaner Villalonga, Mercè Boada Rovira, Ramon Charco Torra, José García Arumí, Albert Pahissa Berga, Josep Sánchez de Toledo Codina, Juan Lorente Guerrero, Miquel Casas Brugué, Monica Anglada Baguena, Miguel Vilardell Tarres, Sara Marsal Barril, Joan Sahuquillo Barris, Cristina Hernández Pascual, Ester Carceller Delgado, Xavier Montalban Gairín
Funding agency: Instituto de Salud Carlos III
Funding: 781267.51
Reference: CAI08/01/0034
Duration: 01/01/2009 - 31/12/2012

CIBER: Diabetes y Enfermedades Metabólicas

IP: Rafael Simó Canonge
Collaborators: Cristina Hernández Pascual, Monica Higuera Urbano
Funding agency: CIBER Diabetes y Enfermedades Metabólicas
Funding: 4200000
Reference: CB07/08/0024
Duration: 01/01/2008 - 01/01/2012

Related news

The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.

The study will validate the safety of a novel topical ocular administration route for sitagliptin.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Mireya Torres Moliner

Mireya Torres Moliner

Predoctoral researcher
Growth and Development
Read more
Marta Palau Requena

Marta Palau Requena

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
González Sánchez Alejandra

González Sánchez Alejandra

Predoctoral researcher
Microbiology
Read more
Cristina Prat Vidal

Cristina Prat Vidal

Postdoctoral researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.